Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02313909 · ClinicalTrials.gov registry record · Phase 3
Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)
A Phase 3 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 7,213
- Enrollment target
NCT02313909 is a Phase 3 study that was terminated before completion, run by Bayer. The registered enrollment target is 7,213 participants.
The verdict
NCT02313909, a Phase 3 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 7,213 participants
- Enrollment target
Study Summary
This is a study in patients who recently had a brain attack (stroke) and in whom no clear cause of the stroke could be identified. These strokes are likely due to a blood clot and therefore, can be called embolic stroke of undetermined source. The abbreviation is ESUS. The study will compare 2 blood thinners. Patients will be randomly assigned to either Rivaroxaban 15 mg or Aspirin 100 mg and the study is intended to show, if patients given rivaroxaban have fewer blood clots in the brain (stroke) or in other blood vessels.
Interventions
- DRUG Rivaroxaban (Xarelto, BAY59-7939)
- DRUG Acetylsalicylic acid (Aspirin, BAY1019036)
- OTHER Rivaroxaban-Placebo
- OTHER Aspirin-Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,213 participants |
| Start Date | 2014-12-23 |
| Est. Completion | 2018-02-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02313909
The ClinicalTrials.gov registry entry for NCT02313909 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 7,213 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Rivaroxaban (Xarelto, BAY59-7939) is the first listed.
NCT02313909 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02313909 about?
NCT02313909 is a clinical study titled "Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)". This is a study in patients who recently had a brain attack (stroke) and in whom no clear cause of the stroke could be identified. These strokes are likely due to a blood clot and therefore, can be called embolic stroke of undetermined source. The abbreviation is ESUS. The study will compare 2 blood...
What is the current status of trial NCT02313909?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 7,213 participants. The study started on 2014-12-23. Estimated completion is 2018-02-15.
What interventions are being tested in trial NCT02313909?
The interventions under investigation include: Rivaroxaban (Xarelto, BAY59-7939) (DRUG), Acetylsalicylic acid (Aspirin, BAY1019036) (DRUG), Rivaroxaban-Placebo (OTHER), Aspirin-Placebo (OTHER).
Who is sponsoring clinical trial NCT02313909?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.